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Abstract
Gram-negative bacillary bacteraemia (GNB) is associated with high morbidity and mortality among cancer patients. We conducted this
study to determine the risk factors that may predict the catheter as the source of GNB in cancer patients. From July 2005 to Decem-
ber 2006 all 266 cancer patients with GNB and central venous catheters (CVCs) at The University of Texas M. D. Anderson Cancer
Centre in Houston, were classiﬁed as catheter-related bloodstream infection (CRBSI) according to Infectious Diseases Society of
America criteria. We compared clinical and microbiological features of CRBSIs and non-CRBSIs. We identiﬁed 78 CRBSIs and 126 non-
CRBSIs. On univariate analysis, polymicrobial bacteraemia, Stenotrophomonas maltophilia bacteraemia, and more than 1000 CFUs in CVC
blood cultures, were more common among CRBSI cases. Escherichia coli bacteraemia, haematologic cancer, neutropenia and prior antibi-
otic use were more common among non-CRBSI cases. On multivariate analysis, S. maltophilia bacteraemia (odds ratio (OR), 5.78; 95%
conﬁdence interval (CI), 1.47–22.78; p 0.045), polymicrobial bacteraemia (OR, 4.04; 95% CI, 1.56–10.44; p 0.042), and more than
1000 CFUs from CVC blood cultures (OR, 4.39; 95% CI, 2.02–9.27; p <0.01), were associated with CRBSI. Neutropenia was associated
with non-CRBSI (OR, 0.26; 95% CI, 0.13–0.53; p <0.01). Several factors such as S. maltophilia bacteraemia, polymicrobial bacteraemia
and more than 1000 CFUs from a blood culture drawn through the CVC may assist the clinicians in assessing whether an indwelling
catheter is the source of a GNB and hence CVC removal may be considered.
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Introduction
Gram-negative bacilli cause a sizeable proportion of nosoco-
mial bloodstream infections in the US. Recent multiannual
and multicentre reports have shown that gram-negative
bacilli cause a similar proportion of nosocomial bacteraemias
in different settings, such as general admissions (25%) [1] and
critical care unit admissions (24%) [2], and among cancer
patients (27%) [3]. At our institution, Raad et al. [4]
also found that one-quarter of bloodstream infections among
cancer patients were caused by a gram-negative organism,
and more than half of bacteraemias were catheter related.
Gram-negative bacteraemias (GNB) have mortality rates of
up to 38%, according to recent reports [5–7]. Patients with
cancer and bacteraemia have higher 30-day mortality than
patients without malignancy [8].
Despite its frequency, there are only a limited number of
studies describing the microbiological and clinical characteris-
tics of gram-negative catheter-related bloodstream infections
(CRBSIs). Hanna et al. [9] reported that early central venous
catheter (CVC) removal is critical in preventing relapse of
gram-negative CRBSI among cancer patients. However, in
many patients with CVCs and GNB, the source of infection is
not related to catheters and removal of the indwelling device
is unnecessary and might deprive severely ill patients of a
needed vascular access. In this current study we aimed to
determine predictors of CRBSI among cancer patients with
CVC and GNB. These clinical and microbiological predictors
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will serve as helpful criteria that will guide clinicians at the bed-
side as to whether the CVC is to be removed or retained.
Patients and Methods
Clinical characteristics
We performed a retrospective study on cancer patients with
GNB and a CVC in place from July 2005 to December 2006
at The University of Texas M. D. Anderson Cancer Centre,
an oncological hospital with 500 beds in Houston, Texas.
The Institutional Review Board approved this study and
waiver of informed consent was obtained.
Blood cultures were processed using the BACTEC 9240
automated culturing system (Plus Aerobic/F bottles; BD Diag-
nostic Systems, Sparks, MD, USA) and the Isolator 10 system
(Wampole Laboratories, Cranbury, NJ, USA). We routinely
performed paired quantitative blood cultures. The number of
colony-forming units had been quantiﬁed from 10 mL of
blood cultured on plates. Time to positivity was recorded for
blood cultures taken from the CVC and peripherally.
We compared patients with CRBSIs with those with non-
CRBSIs in terms of: sex; signs of infection, such as fever, chills,
hypotension, and local inﬂammation at the CVC site; clinical
characteristics, such as neutropenia (deﬁned as an absolute
neutrophil count <500), cancer type (haematological or non-
haematological), admission to the critical care unit, surgery
during the month prior to positive blood culture, total paren-
teral nutrition, mucositis, stem cell transplantation, duration of
CVC use, CVC location and number of lumens, and prior anti-
biotic use; and the microbiological features of the bacteria,
including species, number of colonies, if the blood culture was
polymicrobial (deﬁned as more than one isolate from a single
blood culture) and proportion of multidrug-resistant isolates
(deﬁned as resistant to a quinolone, an aminoglycoside, and an
extended-spectrum cephalosporin).
We assessed concordance by contrasting the predictive
probability calculated for each subject grouped into pairs (one
with CRBSI and one with non-CRBSI) with the actual ﬁndings.
When the predicted probability of CRBSI of the subject with
CRBSI is higher than the probability of the subject with non-
CRBSI we say that the pair is concordant. Conversely, if the
predicted probability of CRBSI is lower for the subject who
did have infection then we say that the pair is discordant.
When the predicted probability is the same, the pair is tied.
Deﬁnitions
Bloodstream infection (BSI) was deﬁned as a recognized
pathogen, isolated from blood culture, that is not related to
infection at another site in a patient who had fever (>38C),
chills or rigors, or hypotension.
Antibiotic exposure was deﬁned as a patient who received
any antibiotic more than 24 h prior to the time when the
positive blood cultures were drawn.
Catheter-related bloodstream infection (CRBSI) was
deﬁned as a BSI plus one of three conditions: ﬁrst, the isolation
of the same organism from quantitative culture of the catheter
tip (>100 CFU/mL) and blood; second, a >3:1 ratio of simulta-
neous quantitative blood cultures drawn from a CVC com-
pared with peripheral blood culture; or third, differential time
to positivity of more than 2 h (blood culture drawn from the
catheter becomes positive at least 2 h earlier than a simulta-
neously drawn peripheral blood culture) [10].
Statistical analysis
We compared categorical variables using the chi-square test
and Fisher’s exact test when appropriate. We determined
whether our recorded continuous variables followed a nor-
mal distribution using the Shapiro–Wilk test. We used the
Wilcoxon test to compare the distribution of these variables
between CRBSI and non-CRBSI cases. We included all vari-
ables whose tests for association with CRBSI rendered a
p-value of £0.25 in a multiple logistic regression model and
tested in a descending way. All tests were two tailed, with a
level of signiﬁcance of 0.05. We used SAS software version 9
(SAS Institute, Cary, NC, USA) for all statistical analyses.
Results
From July 2005 to December 2006, there were 623 episodes
of bacteraemia (Fig. 1) among cancer patients with CVCs. In
266 cases (42.7%), at least one isolate was identiﬁed as
gram-negative bacilli. Seventy-eight cases of GNB were classi-
ﬁed as deﬁnite CRBSI, whereas 126 were classiﬁed as non-
CRBSIs. Another 62 cases were classiﬁed probable CRBSI
and excluded from the analysis.
FIG. 1. Flow chart showing selection of patients.
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Univariate analysis
The age distribution was similar between patients with CRB-
SIs and those with non-CRBSIs (median age, 59 years for
CRBSI patients vs. 56 years for non-CRBSI patients, p 0.68).
Both groups had a similar sex distribution (50% male for
CRBSIs vs. 56% for non-CRBSIs; p 0.44). The median dura-
tion of CVC use was also similar (58.5 days for CRBSIs vs.
42.0 days for non-CRBSIs; p 0.12). There was a similar pro-
portion of patients with a CVC in place for at least 50 days
in both groups (53% of those with CRBSIs vs. 44% of those
with non-CRBSIs; p 0.18).
There were statistically signiﬁcant differences in the
microbiological characteristics of CRBSIs and non-CRBSIs
(Fig. 2). Escherichia coli was found more frequently in non-
CRBSI cases than in CRBSI cases (33% vs. 15%; p 0.005).
Conversely, Stenotrophomonas maltophilia was more common
in CRBSIs (3% non-CRBSIs vs.14% CRBSIs; p 0.004). Two-
thirds (36 of 54) of CVC blood cultures with a colony count
of >1000 CFUs were from patients with CRBSIs (p <0.0001).
Only 15 of 204 GNB isolates were multidrug resistant (resis-
tance to an aminoglycoside, a cephalosporin and a quino-
lone). These isolates found were equally apportioned
between CRBSI and non-CRBSI patients (4% and 10%,
respectively; p 0.13).
Systemic and local signs of infection were similarly distrib-
uted in both groups (Table 1). Patients with CRBSI were less
likely to have a haematological malignancy than those with a
non-CRRBSI (64% vs. 81%; p 0.007). One hundred and eigh-
teen patients had neutropenia; 100 of these patients (93%)
had haematological malignancies. Neutropenia was also
strongly associated with non-CRBSIs (36% among CRBSIs vs.
71% among non-CRBSIs; p <0.0001). Patients with CRBSIs
and non-CRBSIs had similar distributions of other presump-
tive risk factors for bacteraemia, including stem cell trans-
plantation (13% in patients with CRBSIs vs. 10% in patients
with non-CRBSIs; p 0.58), admission to the critical care unit
(9% vs. 11%; p 0.63), prior surgery (3% vs. 6%; p 0.49), total
parenteral nutrition (3% vs. 1%; p 0.56), mucositis (6% vs.
8%; p 0.61), and graft-versus-host disease (4% vs. 0%;
p 0.06). Thirty-eight of 78 patients with CRBSIs had previ-
ously used antibiotics vs. 86 of 126 with non-CRBSIs
(p 0.006). Three of four antibiotic prescriptions were given
as prophylaxis.
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FIG. 2. Microbilogy of CRBSI and non-CRBSI among hospitalized cancer patients with central venous catheter.
TABLE 1. Relationships between clinical variables and
gram-negative CRBSI
Variable
CRBSI
(n = 78)
Non-CRBSI
(n = 126) p-value
Male sex, n (%) 39 (50) 70 (56) 0.44
Median age, years 59 56 0.68
Fever, n (%) 64 (82) 100 (79) 0.64
Chills, n (%) 17 (22) 17 (14) 0.12
Hypotension, n (%) 13 (17) 19 (15) 0.76
Local tenderness, n (%) 0 (0) 5 (4) 0.16
Neutropenia, n (%) 28 (36) 90 (71) <0.0001
Haematological malignancy, n (%) 50 (64) 102 (81) 0.0073
Critical care unit admission, n (%) 7 (9) 14 (11) 0.63
Previous surgery, n (%) 2 (3) 7 (6) 0.49
Total parenteral nutrition, n (%) 2 (3) 1 (1) 0.56
Mucositis, n (%) 5 (6) 10 (8) 0.61
Stem cell transplantation, n (%) 10 (13) 13 (10) 0.58
Graft-versus-host disease, n (%) 3 (4) 0 (0) 0.06
Median duration of catheterization,
days
58.5 42 0.12
CVC in place ‡50 days, n (%) 41 (53) 56 (44) 0.18
Multiple-lumen CVC, n (%) 65 (83) 98 (78) 0.34
Catheter location 0.67
Subclavian 56 (76) 83 (67)
Jugular 3 (4) 4 (3)
Femoral 0 (0) 1 (1)
Cephalic 2 (3) 5 (4)
Basilic 13 (18) 30 (24)
Antibiotics exposure, n (%) 38 (49) 86 (68) 0.0055
BSI organism, n (%)
S. maltophilia 11 (14) 4 (3) 0.0037
E. coli 12 (15) 42 (33) 0.0047
Acinetobacter spp. 8 (10) 4 (3) 0.06
E. cloacae 10 (13) 8 (6) 0.11
Klebsiella spp. 14 (18) 13 (10) 0.12
P. aeruginosa 18 (23) 37 (29) 0.32
Polymicrobial bacteraemia 23 (30) 12 (10) 0.0002
Other GNB, n (%) 15 (19) 20 (16) 0.53
>1000 CFUs from CVC, n (%) 36 (46) 18 (14) <0.0001
Multidrug-resistant G – bacilli, n (%) 3 (4) 12 (10) 0.13
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Multivariate analysis
We included all variables with a p-value for association with
CRBSI of 0.25 or less (polymicrobial bacteraemia; high col-
ony count (>1000 CFUs) by CVC; E. coli, Klebsiella spp.,
Acinetobacter spp., E. cloacae, S. maltophilia and multidrug-
resistant GNB; cancer type; neutropenia; graft-versus-host-
disease; prior antibiotic use; chills; duration of catheterization
‡50 days; and local tenderness at the CVC insertion site) in
a logistic regression model. In this multivariate analysis, the
factors independently associated with CRBSI were S. malto-
philia bacteraemia (odds ratio (OR), 5.78; 95% conﬁdence
interval (CI), 1.47–22.78), polymicrobial bacteraemia (OR,
4.04; 95% CI, 1.56–10.44), more than 1000 CFUs on CVC
blood culture (OR, 4.39; 95% CI, 2.02–9.57), and neutrope-
nia (OR, 0.26; 95% CI, 0.13–0.53) (Table 2). When we used
a predictive probability of more than 0.6 as an arbitrary
cut-off for diagnosis of CRBSI our model had a sensitivity of
50%, speciﬁcity of 95%, false-positive rate of 14.6% and false-
negative rate of 23.5%.
Discussion
Our data show signiﬁcant differences in the microbiological
and clinical characteristics of CRBSI vs. non-catheter-related
GNB. S. maltophilia and polymicrobial bacteraemia, as well as
high colony counts (>1000 CFU/mL) in a blood culture
drawn through a CVC, characterized patients with CRBSI,
while neutropenia was signiﬁcantly more likely among
patients with bacteraemia unrelated to catheters.
On univariate analysis, E. coli was a more common cause
of bacteraemia, unrelated to CVC use. Martino [11] found
that enterobacteriaceae, a group that included E. coli, caused
more bacteraemia of unknown source and were less often
catheter-related than other gram-negative bacilli among
patients with haematological malignancies. Cytotoxic chemo-
therapy often affects the gastrointestinal tract of many can-
cer patients [12]. Normal gut ﬂora, which include E. coli and
other enterobacteriaceae, can subsequently gain access to the
bloodstream. Conversely, S. maltophilia was associated with
CRBSIs, and this effect was independent of any other tested
variable in our logistic regression model. Boktour et al. [13]
previously found that most S. maltophilia bacteraemias in can-
cer patients were CVC related and also noted that those
cases had a better response to antibiotics than did other
S. maltophilia infections if the CVC was also removed. Bioﬁlm
formation seems to be mediated by S. maltophilia ﬁmbriae
[14] and enhanced by other features such as hydrophobicity
and less motility among S. maltophilia strains [15,16]. Bioﬁlm
formation may also be affected by physical factors [17] and
antibiotic use [18].
Polymicrobial GNB was more common among CRBSI
cases than among non-CRBSI cases. Bioﬁlms have been
described as being composed of multiple bacteria arranged in
microcolonies [19,20]. Furthermore, polymicrobial bactera-
emia is not uncommon in cancer patients [21]. Klastersky
et al. [22] reported that 10% of bacteraemias among cancer
patients with febrile neutropenia involved two or more bac-
teria types. This association is worrisome because polymi-
crobial bacteraemias have a higher mortality rate than do
those with a single isolate [23]. In cancer patients, Elting
et al. [24] found that polymicrobial BSI also had a lower
response rate to antibiotics. In CRBSIs, the source of the
infection can be removed, which has been found to help pre-
vent relapses in gram-negative CRBSI [9]. Further investiga-
tion is needed regarding the epidemiological characteristics
of polymicrobial bloodstream infections in cancer patients
and the mechanisms required to prevent colonization of
indwelling devices by multiple organisms.
Neutropenia is a known risk factor for GNB [25–28]. How-
ever, in this current study, we found that neutropenia was
independently associated with non-CRBSIs. Our results are
consistent with those of Boktour et al. [13], who found that
neutropenic patients with S. maltophilia bacteraemia were less
likely to have a CRBSI. In another study at our institution, Raad
et al. [4] reported that the proportion of GNBs classiﬁed as
CRBSIs among the predominantly neutropenic patients with
haematologic malignancy was signiﬁcantly lower than that
among solid tumour patients [4]. This effect was not seen
among patients with gram-positive infections. On further anal-
ysis, most of the difference could be explained by a high fre-
quency of neutropenia among patients with haematological
malignancies compared with patients with solid tumours.
Therefore, patients with neutropenia in our study may have
been at higher risk of bacteraemia from a different, non-cathe-
ter, source such as their gastrointestinal or genitourinary tract.
A quantitative blood culture from the CVC of
>1000 CFUs was strongly associated with CRBSI. Capdevila
et al. [29] proposed that a high colony count (>100 CFUs)
on blood culture drawn from the CVC, along with peripheral
TABLE 2. Individual factors independently associated with
gram-negative CRBSI on multiple logistic regression analy-
sis
Effect
OR
estimate 95% CI limit
S. maltophilia bacteraemia 5.78 1.47 22.78
Polymicrobial bacteraemia 4.04 1.56 10.44
>1000 CFUs from CVC 4.39 2.02 9.57
Neutropenia 0.26 0.13 0.53
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blood culture positive for the same organism, was an accu-
rate diagnostic tool for CRBSI. Similarly, Safdar et al. [30]
conducted a meta-analysis and estimated a pooled sensitivity
of 84% and speciﬁcity of 90% for a high colony count
(>100 CFU/mL) in a quantitative blood culture drawn
through the CVC in establishing the diagnosis of CRBSI.
Although a high colony count from a CVC blood culture by
itself is not diagnostic of CRBSI, it is reasonable to use this
test for screening purposes with a low threshold for CVC
removal or exchange in cancer patients with GNB.
There were certain limitations to our study. We were
unable to ascertain retrospectively where the infection was
acquired. This was a retrospective study. Factors negatively
associated with CRBSIs are not necessarily protective
against CRBSIs but rather are more common in other types
of infection. We did not record information regarding the
presence of abdominal symptoms such as diarrhoea and
abdominal pain that may indicate the possibility of colitis or
the source of gram-negative bacteraemia. In addition, this
was a single-centre study focused on cancer patients. The
results may not be translated to a general population.
Several factors may assist clinicians in making a decision as
to when a CVC is the source of a GNB and hence CVC
removal may be considered. Our analysis of 204 gram-negative
BSI cases revealed intriguing differences in the microbiological
and clinical characteristics of CRBSIs vs. non-CRBSIs. S. malto-
philia is a common cause of gram-negative CRBSI; polymicrobi-
al infections are also strongly suggestive of a CRBSI. A high
colony count obtained from a quantitative blood culture
drawn through a CVC is a strong predictor of CRBSI. Hence, a
low threshold for CVC removal maybe warranted in all of
these situations. Neutropenic patients are probably at a higher
risk of bacteraemia from sources besides the CVC.
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